In a notable display of insider activity, Todd Hannigan, serving as Executive Chairman for IperionX Ltd (NASDAQ: IPX), has significantly expanded his position in the company through the purchase of ordinary shares. These transactions, conducted on the Australian Stock Exchange, represent an investment of roughly $2,077,784.
The acquisition took place over a 48-hour window in late April 2026. On April 28, 2026, Mr. Hannigan bought 220,000 ordinary shares at an average cost of A$4.4819 per share. The following day, April 29, 2026, he added another 260,000 shares to his portfolio at a price of A$4.1991 per share. These specific purchases were made as direct holdings and bring his total directly owned ordinary shares to 26,108,334.
Market Context and Valuation
This insider buying occurs within a complex period for IPX stock performance. While the company's shares have seen a decline of 34% over the last six months, they have nevertheless achieved a gain of 32% over the past year. Currently, the stock is trading at $29.05, with IperionX maintaining a market capitalization of approximately $1 billion.
Despite recent half-year volatility, market sentiment remains optimistic among analysts, who maintain a strong buy consensus. Price targets provided by analysts range from a low of $40 to a high of $71, indicating a potential for significant upside from current levels.
Comprehensive Executive Holdings
Mr. Hannigan's interest in IperionX is reflected across various types of equity and derivative instruments. In addition to his ordinary shares, he directly holds 454,464 Restricted Stock Units (RSUs). The vesting schedule for these units is divided into two stages: 159,334 are set to vest in December 2026, while the remaining 295,130 are scheduled for vesting in April 2028.
Furthermore, his holdings include several layers of performance rights and options that are convertible into ordinary shares:
- Performance Rights: He holds three separate blocks of 306,302 performance rights each, with exercise prices set at A$6, A$7, and A$8 respectively. These are all exercisable by April 10, 2029, and expire on April 10, 2030.
- Secondary Performance Rights/Options: He also possesses 196,086 performance rights and 465,410 options with an exercise price of A$18. These are exercisable by April 2, 2030, and expire on April 2, 2031.
- High-Value Options: An additional 526,760 options are held at an exercise price of A$22, sharing the same exercise date of April 2, 2030, and expiration date of April 2, 2031.
Finally, Mr. Hannigan directly holds 50,000 American Depository Shares (ADS) of IperionX that trade on the Nasdaq. Each ADS is exchangeable for ten ordinary shares.
Operational Milestones and Analyst Outlook
IperionX has reached a critical phase in its industrial operations with the commencement of commercial production at its facility located in Virginia. The company's current objective is to reach an annual production rate of approximately 200 tonnes of titanium this year. Looking ahead to next year, IperionX intends to scale these operations significantly to reach an annual output of roughly 1,400 tonnes.
This operational expansion aligns with the company's efforts to address rising demand within the titanium market. Highlighting this trajectory, BTIG recently initiated coverage on IperionX Ltd with a Buy rating and a price target of $40.00, reflecting institutional confidence in the company's strategic path and growth potential.